GlucoTrack is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April. At this time, GlucoTrack's Other Stockholder Equity is quite stable compared to the past year. Net Tangible Assets is expected to rise to about 1.5 M this year, although the value of Total Current Liabilities will most likely fall to about 1.7 M. Key indicators impacting GlucoTrack's financial strength include:
The financial analysis of GlucoTrack is a critical element in measuring its lifeblood. Investors should not minimize GlucoTrack's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income
(6.71 Million)
GlucoTrack
Select Account or Indicator
Price To Sales Ratio
Dividend Yield
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Average Inventory
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Payout Ratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Dividend Payout Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Dividends Paid
Change To Inventory
Change To Account Receivables
Total Cashflows From Investing Activities
Change To Operating Activities
Change To Netincome
Change To Liabilities
Investments
Issuance Of Capital Stock
Common Stock Shares Outstanding
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Accumulated Other Comprehensive Income
Common Stock
Short Term Debt
Net Receivables
Inventory
Net Tangible Assets
Other Assets
Property Plant Equipment
Long Term Debt
Net Invested Capital
Capital Stock
Net Working Capital
Property Plant And Equipment Gross
Depreciation And Amortization
Interest Expense
Selling General Administrative
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Tax Expense
Income Before Tax
Total Other Income Expense Net
Total Revenue
Gross Profit
Selling And Marketing Expenses
Net Income Applicable To Common Shares
Net Interest Income
Net Income From Continuing Ops
Reconciled Depreciation
Cost Of Revenue
Interest Income
Probability Of Bankruptcy
Understanding current and past GlucoTrack Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of GlucoTrack's financial statements are interrelated, with each one affecting the others. For example, an increase in GlucoTrack's assets may result in an increase in income on the income statement.
GlucoTrack competes with Nexgel, Sharps Technology, Innovative Eyewear, Predictive Oncology, and Microbot Medical. GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel. Glucotrack operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 5 people.
Comparative valuation techniques use various fundamental indicators to help in determining GlucoTrack's current stock value. Our valuation model uses many indicators to compare GlucoTrack value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across GlucoTrack competition to find correlations between indicators driving GlucoTrack's intrinsic value. More Info.
GlucoTrack is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, GlucoTrack's Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value GlucoTrack by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
GlucoTrack Systematic Risk
GlucoTrack's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. GlucoTrack volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on GlucoTrack correlated with the market. If Beta is less than 0 GlucoTrack generally moves in the opposite direction as compared to the market. If GlucoTrack Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one GlucoTrack is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of GlucoTrack is generally in the same direction as the market. If Beta > 1 GlucoTrack moves generally in the same direction as, but more than the movement of the benchmark.
GlucoTrack Thematic Clasifications
GlucoTrack is part of Drugs investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery
This theme covers Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery. Get More Thematic Ideas
Today, most investors in GlucoTrack Stock are looking for potential investment opportunities by analyzing not only static indicators but also various GlucoTrack's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of GlucoTrack growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of GlucoTrack help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of GlucoTrack. We use our internally-developed statistical techniques to arrive at the intrinsic value of GlucoTrack based on widely used predictive technical indicators. In general, we focus on analyzing GlucoTrack Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build GlucoTrack's daily price indicators and compare them against related drivers.
When determining whether GlucoTrack is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlucoTrack Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glucotrack Stock. Highlighted below are key reports to facilitate an investment decision about Glucotrack Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlucoTrack. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy GlucoTrack Stock please use our How to buy in GlucoTrack Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlucoTrack. If investors know GlucoTrack will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlucoTrack listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(58.20)
Return On Assets
(2.04)
Return On Equity
(19.43)
The market value of GlucoTrack is measured differently than its book value, which is the value of GlucoTrack that is recorded on the company's balance sheet. Investors also form their own opinion of GlucoTrack's value that differs from its market value or its book value, called intrinsic value, which is GlucoTrack's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlucoTrack's market value can be influenced by many factors that don't directly affect GlucoTrack's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlucoTrack's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlucoTrack is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlucoTrack's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.